通过生物信息学验证RN1H4基因预测尤文肉瘤患者预后的作用
Verifying the Function of RN1H4 Gene Predicting Prognosis of Ewing Sarcoma by Bioinformatics
DOI: 10.12677/ACM.2022.123253, PDF,   
作者: 孙 楷, 于 壮*:青岛大学附属医院,山东 青岛;王春燕:潍坊市坊子区人民医院,山东 潍坊
关键词: 生物信息学尤文肉瘤预后RN1H4GEO数据库Bioinformatics Ewing Sarcoma Prognosis RN1H4 GEO Database
摘要: 尤文肉瘤是恶性程度极高的骨原发肿瘤,好发于儿童和青少年。尤文肉瘤预后极差,具有高度的侵袭性,在青少年儿童肿瘤发病率中排在第二位。我们基于GEO数据库(Gene Expression Omnibus)中尤文肉瘤相关的数据,构建了一个由7个基因构成的风险分数计算模型。该模型联合年龄性别构建的预测模型可用于预测患者预后。在该风险分数计算模型中,筛选出了RN1H4基因。该基因在高风险组中显著表达。RN1H4高表达患者预后较差,辅助T细胞、单核细胞、中性粒细胞和树突细胞的浸润和RN1H4基因的表达量具有显著相关性。这些细胞浸润丰度也显著影响了病人预后。我们又检测了RN1H4基因高低表达两组差异基因。对差异基因做了GO和KEGG分析,预测了RN1H4在尤文肉瘤中发挥的作用。揭示了RN1H4在尤文肉瘤中的作用机制。
Abstract: Ewing sarcoma is a highly malignant primary tumor of bone, usually occurring in children and adolescents. Ewing sarcoma has a very poor prognosis and is highly aggressive, ranking second in the incidence of tumors in children and adolescents. We constructed a risk score calculation model consisting of 7 genes based on Ewing sarcoma data from the GEO Database (Gene Expression Omnibus). The prediction model combined with age and sex can be used to predict the prognosis of patients. The RN1H4 gene was screened from the risk score model. The gene was significantly expressed in the high-risk group. The prognosis of patients with high expression of RN1H4 was poor, and the infiltration of helper T cells, monocytes, neutrophils and dendritic cells was significantly correlated with the expression of RN1H4. The abundance of these infiltrates also significantly affected patient outcomes. We also detected the high and low expression of RN1H4 gene. GO and KEGG enrichment analyses were performed to predict the role of RN1H4 in Ewing’s sarcoma. The mechanism of RN1H4 in Ewing’s sarcoma was revealed.
文章引用:孙楷, 王春燕, 于壮. 通过生物信息学验证RN1H4基因预测尤文肉瘤患者预后的作用[J]. 临床医学进展, 2022, 12(3): 1758-1768. https://doi.org/10.12677/ACM.2022.123253

参考文献

[1] Ewing J. (1972) Classics in Oncology. Diffuse Endothelioma of Bone. CA: A Cancer Journal for Clinicians, 22, 95-98. [Google Scholar] [CrossRef] [PubMed]
[2] Grünewald, T.G.P., Cidre-Aranaz, F., Surdez, D., Tomazou, E.M., de Álava, E., Kovar, H., Sorensen, P.H., Delattre, O. and Dirksen, U. (2018) Ewing Sarcoma. Nature Reviews Disease Primers, 4, Article No. 5.
[3] Gaspar, N., Hawkins, D.S., Dirksen, U., Lewis, I.J., Ferrari, S., Le Deley, M.C., et al. (2015) Ewing Sarcoma: Current Management and Future Approaches through Collaboration. Journal of Clinical Oncology, 33, 3036-3046. [Google Scholar] [CrossRef
[4] Balamuth, N.J and Womer, R.B. (2010) Ewing’s Sarcoma. The Lancet Oncology, 11, 184-192. [Google Scholar] [CrossRef
[5] (2018) Ewing Sarcoma. Nature Reviews Disease Primers, 4, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[6] 刘杰, 赵田, 李钦传, 陈国涵. 肺癌免疫治疗进展[J/OL]. 中国胸心血管外科临床杂志: 1-9. http://kns.cnki.net/kcms/detail/51.1492.r.20220126.1110.024.html, 2022-02-09.
[7] de Aguiar Vallim, T.Q., Tarling, E.J. and Edwards, P.A. (2013) Pleiotropic Roles of Bile Acids in Metabolism. Cell Metabolism, 17, 657-669. [Google Scholar] [CrossRef] [PubMed]
[8] Lee, Y.J., Lee, E.Y., Choi, B.H., Jang, H., Myung, J.K. and You, H.J. (2020) The Role of Nuclear Receptor Subfamily 1 Group H Member 4 (NR1H4) in Colon Cancer Cell Survival through the Regulation of c-Myc Stability. Molecules and Cells, 43, 459-468.
[9] Savola, S., Klami, A., Myllykangas, S., Manara, C., Manara, C., Scotlandi, K., et al. (2011) High Expression of Complement Component 5 (C5) at Tumor Site Associates with Superior Survival in Ewing’s Sarcoma Family of Tumour Patients. International Scholarly Research Notices, 2011, Article ID: 168712. [Google Scholar] [CrossRef] [PubMed]
[10] Bailey, A.M., Zhan, L., Maru, D., Shureiqi, I., Pickering, C.R., Kiriakova, G., Izzo, J., He, N., Wei, C., Baladandayuthapani, V., Liang, H., Kopetz, S., Powis, G. and Guo, G.L. (2014) FXR Silencing in Human Colon Cancer by DNA Methylation and KRAS Signaling. American Journal of Physiology-Gastrointestinal and Liver, 306, G48-G58. [Google Scholar] [CrossRef] [PubMed]
[11] Jiang, L., Zhang, H., Xiao, D., Wei, H. and Chen, Y. (2021) Farnesoid X Receptor (FXR): Structures and Ligands. Computational and Structural Biotechnology Journal, 19, 2148-2159. [Google Scholar] [CrossRef] [PubMed]
[12] Volchenboum, S.L., Andrade, J., Huang, L., Barkauskas, D.A., Krailo, M., Womer, R.B., et al. (2015) Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children’s Oncology Group. The Journal of Pathology: Clinical Research, 1, 83-94. [Google Scholar] [CrossRef] [PubMed]
[13] Yu, G., Wang, L.-G. Han, Y. and He, Q.-Y. (2012) clusterProfiler: An R Package for Comparingbiological Themes among Gene Clusters. OMICS: A Journal of Integrative Biology, 16, 284-287. [Google Scholar] [CrossRef] [PubMed]
[14] Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W. and Smyth, G.K. (2015). Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies. Nucleic Acids Research, 43, e47.[CrossRef] [PubMed]
[15] Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang, C.D., Diehn, M. and Alizadeh, A.A. (2015) Robust Enumeration of Cell Subsets from Tissue Expression Profiles. Nature Method, 12, 453-457. [Google Scholar] [CrossRef] [PubMed]
[16] Riggi, N., Suvà, M.L. and Stamenkovic, I. (2021) Ewing’s Sarcoma. New England Journal of Medicine, 384, 154-164. [Google Scholar] [CrossRef
[17] Eaton, B.R., Claude, L., Indelicato, D.J., Vatner, R., Yeh, B., Schwarz, R. and Laack, N. (2021) Ewing Sarcoma. Pediatric Blood & Cancer, 68, e28355. [Google Scholar] [CrossRef] [PubMed]
[18] Zöllner, S.K., Amatruda, J.F., Bauer, S., Collaud, S., de Álava, E., DuBois, S.G., Hardes, J., Hartmann, W., Kovar, H., Metzler, M., Shulman, D.S., Streitbürger, A., Timmermann, B., Toretsky, J.A., Uhlenbruch, Y., Vieth, V., Grünewald T.G.P. and Dirksen, U. (2021) Ewing Sarcoma-Diagnosis, Treatment, Clinical Challenges and Future Perspectives. Journal of Clinical Medicine, 10, Article No. 1685. [Google Scholar] [CrossRef] [PubMed]
[19] Pappo, A.S. and Dirksen, U. (2018) Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. Journal of Clinical Oncology, 36, 168-179. [Google Scholar] [CrossRef
[20] Morales, E., Olson, M., Iglesias, F., Dahiya, S., Luetkens, T. and Atanackovic, D. (2020) Role of Immunotherapy in Ewing Sarcoma. Journal for ImmunoTherapy of Cancer, 8, e000653. [Google Scholar] [CrossRef] [PubMed]
[21] Luo, C., Wei, J. and Han, W. (2016) Spotlight on Chimeric Antigen Receptor Engineered T Cell Research and Clinical Trials in China. Science China Life Sciences, 59, 349-359. [Google Scholar] [CrossRef] [PubMed]